Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001897612-25-000365
Filing Date
2025-08-14
Accepted
2025-08-14 12:12:13
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 7537
  Complete submission text file 0001897612-25-000365.txt   9213
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Subject) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-87705 | Film No.: 251216254
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1307 POINT STREET BALTIMORE MD 21231
Business Address 1307 POINT STREET BALTIMORE MD 21231 000-000-0000
T. Rowe Price Investment Management, Inc. (Filed by) CIK: 0001897612 (see all company filings)

EIN.: 854328500 | State of Incorp.: MD | Fiscal Year End: 1231
Type: SCHEDULE 13G